{"id":17872,"date":"2021-08-25T13:09:02","date_gmt":"2021-08-25T11:09:02","guid":{"rendered":"https:\/\/www.izb-online.de\/dr-sabine-hauk-wird-senior-vp-corporate-development-der-leukocare-ag\/"},"modified":"2021-09-23T13:51:06","modified_gmt":"2021-09-23T11:51:06","slug":"dr-sabine-hauk-wird-senior-vp-corporate-development-der-leukocare-ag","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/dr-sabine-hauck-becomes-senior-vp-corporate-development-of-leukocare-ag\/","title":{"rendered":"Dr. Sabine Hauck becomes Senior VP Corporate Development of Leukocare AG"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Dr. Sabine Hauck becomes Senior VP Corporate Development of Leukocare AG<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]The expert in formulation development is now taking the company forward at a strategic level[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]August 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”17869″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Leukocare AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Sabine Hauck, Senior Vice President Corporate Development bei Leukocare[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cIt is a great pleasure to take up the role as Senior VP Corporate Development. Since the time I joined Leukocare in 2017, my goal has always been to support the company\u00b4s development not only in terms of R&D but also on a strategic level. Thus, I am delighted to be in a position to make a decisive contribution to Leukocare\u00b4s corporate development.\u201d<\/h6>\n

Dr. Sabine Hauck
\nSenior Vice President Corporate Development at Leukocare<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Dr. Sabine Hauck headed the R&D department at Leukocare for the last four years. In her new role as Senior Vice President Corporate Development, Sabine is responsible for aligning strategic and technical goals to provide customers with tailor-made solutions in the field of drug product formulation development for biopharmaceuticals. Sabine has 20 years of drug product development expertise as well as several years of in vitro diagnostic and biosensor development. Before joining Leukocare, Sabine was heading Pharmaceutical Development, Quality Assurance and Regulatory Affairs departments at Medigene AG, Martinsried, Germany, Acino International AG, Zurich, Switzerland and IDEA Pharma AG, Basel, Switzerland and Munich, Germany. She holds a Dr. rer. nat. from University of Regensburg, Germany.<\/p>\n

Dr. Sabine Hauck, Senior Vice President Corporate Development at Leukocare, said, \u201cIt is a great pleasure to take up the role as Senior VP Corporate Development. Since the time I joined Leukocare in 2017, my goal has always been to support the company\u00b4s development not only in terms of R&D but also on a strategic level. Thus, I am delighted to be in a position to make a decisive contribution to Leukocare\u00b4s corporate development\u201d.<\/p>\n

\u201cI am extremely happy to have Sabine taking over as Senior VP Corporate Development. In her new position, she will play a decisive role in further driving Leukocare\u2019s strategy to meet our customers\u2019 needs at the best,\u201d explains Michael Scholl, CEO Leukocare AG[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n